COLUMBIA, Md.--(BUSINESS WIRE)--Chesapeake IRB, the leading technology-enabled independent institutional review board (IRB) serving the clinical research industry, announced it has acquired MaGil IRB, a central IRB located in Rockville, Md.
The MaGil acquisition provides Chesapeake with additional AAHRPP-accredited review capacity and a talented staff that further broadens Chesapeake’s presence for CROs, pharmaceutical companies and biotech companies. This marks Chesapeake’s fifth acquisition of an AAHRPP-accredited IRB since 2013, further positioning itself as the best IRB to support the growth in the clinical research industry.
“Today we are delighted to welcome MaGil IRB to the Chesapeake family,” said Jeff Wendel, president and CEO of Chesapeake. “Together, we are even better positioned to deliver unparalleled human subject protections and oversight and exceptional client service.”
“Joining with Chesapeake allows MaGil customers to benefit from Chesapeake’s innovative cloud-based IRB platform, CIRBI, while continuing the joint mission of safeguarding the rights and welfare of clinical research participants,” said Gil Price, co-founder and CEO of MaGil IRB.
About Chesapeake IRB
Chesapeake IRB, an AAHRPP-accredited company, provides independent IRB submission and review services to pharmaceutical, biotech, and medical device companies, as well as academic medical centers and hospital systems. Its paperless, cloud-based submission and review platform, CIRBI, leads the field and has set the standard in review turnaround time, quality, and document accessibility. Headquartered in Columbia, MD, Chesapeake IRB has offices across the United States and a wholly owned subsidiary, IRB Services, with offices in Toronto and Montreal, Canada. Visit chesapeakeirb.com for more information.